N/A
N=10
V2 Receptor Effects on Fluid Regulation and Performance
Electrolyte Imbalance · Hyponatremia · Hypernatremia
Bottom Line
View on ClinicalTrials.gov: NCT02084797 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
May 2016
Primary outcome: Primary: Sweat Sodium Concentration Obtained After the Steady-state Portion of the Trial — 80.1; 76.8; 84.7 mEq/L
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- V2R (Vasopressin 2 receptor) (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Oakland University
- Primary completion
- Oct 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Sweat Sodium Concentration Obtained After the Steady-state Portion of the Trial |
80.1; 76.8; 84.7 | — |
| SECONDARY Urine Sodium Concentration After the Steady-state Portion of the Trial |
82.0; 89.3; 16.4 | — |
| SECONDARY Blood Sodium Concentration |
143.6; 144.3; 145.9 | — |
| SECONDARY Saliva Sodium Concentration |
20.5; 28.1; 31.0 | — |
Summary
This primary aim of this study was to critically assess whether or not sweat water content and sodium concentration were acutely regulated by dynamic changes in antidiuretic hormone (arginine vasopressin or AVP) acting on the Vasopressin 2 receptor (V2R) during exercise. Secondary aims were to evaluate running performance and core temperature to further characterize the role of AVP in the coordinated balance of fluid and temperature homeostasis during exercise. The primary hypothesis was that activation of the V2R in sweat glands would result in water reabsorption and fluid conservation during endurance exercise.
Eligibility Criteria
Inclusion Criteria
- Healthy (no acute or chronic medical conditions or regular prescription medication use), habitual (>50km/week)
- Distance runners between the ages of 18-60 years.
Exclusion Criteria
- Individuals with chronic medical problems which require regular prescription medication
- Runners with pre-existing kidney problems
- Unable to sense thirst
- Difficulty swallowing
- Gastrointestinal disorders
- History of fainting associated with blood draw.
Data sourced from ClinicalTrials.gov (NCT02084797). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.